Things That Multiple Sclerosis Patients Should Avoid

Featured Article

According to a new study, Tysabri significantly increases the proportion of disease-free patients with relapsing multiple sclerosis (MS) compared with placebo after two years. In the study, 942 MS patients were given either intravenous Tysabri or a placebo once every four weeks for up to 116 weeks. Researchers found that the proportion of disease-free patients was significantly higher in the Tysabri group compared with the placebo group.

Read more

More information on "Things That Multiple Sclerosis Patients Should Avoid"

From Our Experts

See more SharePosts »